IDH-mutant glioma
Drugs
Every IDH-mutant glioma program in this file, grouped by class. Open a drug for its studies and the sources behind each figure.
ClassNone selected
All programs shown
15 of 15 programs shown
alkylating chemotherapy 2 drugs
- RT With Or Without Temozolomide (E3F05)ECOG-ACRINPhase 3temozolomide, oral. Treatment type: radiotherapy1 studyalkylating chemotherapy
- Temozolomide Vs PCV With RT (CODEL)AlliancePhase 3temozolomide, oral. procarbazine, oral. lomustine, oral. vincristine, intravenous. Treatment type: radiotherapy1 studyalkylating chemotherapy
ATR inhibitor (ATRX-altered) 1 drug
- TuvusertibGEINOPhase 2Route n/r1 studyATR inhibitor (ATRX-altered)
DNMT inhibitor 1 drug
- ASTX727 (decitabine/cedazuridine)Massachusetts General HospitalPhase 1oral1 studyDNMT inhibitor
mutant IDH1 inhibitor 3 drugs
- IvosidenibServierPhase 1oral1 studymutant IDH1 inhibitor
- OlutasidenibRigelPhase 2oral2 studiesmutant IDH1 inhibitor
- Safusidenib (AB-218, DS-1001)Nuvation BioPhase 3oral5 studiesmutant IDH1 inhibitor
mutant IDH1/IDH2 inhibitor 2 drugs
- HMPL-306 (ranosidenib)HutchmedPhase 3oral2 studiesmutant IDH1/IDH2 inhibitor
- VorasidenibVoranigoServierApprovedoral9 studiesmutant IDH1/IDH2 inhibitor
PARP inhibitor 3 drugs
- NiraparibMassachusetts General HospitalPhase 1oral1 studyPARP inhibitor
- OlaparibHospices Civils de Lyon (OLAGLI)Phase 2oral3 studiesPARP inhibitor
- Pamiparib + TemozolomideUniversity of California, San FranciscoPhase 1oral1 studyPARP inhibitor
PD-1 antibody 1 drug
- NivolumabNational Cancer InstitutePhase 2intravenous1 studyPD-1 antibody
peptide vaccine 1 drug
- IDH1-VAC (IDH1 R132H Peptide Vaccine)German Cancer Research CenterPhase 2subcutaneous3 studiespeptide vaccine
retinoid plus PD-1 antibody 1 drug
- Tretinoin (ATRA) + RetifanlimabUniversity of Pennsylvania (Stephen Bagley)Phase 2tretinoin, oral. retifanlimab, intravenous1 studyretinoid plus PD-1 antibody